Local Infiltration Analgesia for Hip Arthroscopy
This study has been completed.
Sponsor:
Saint Francis Care
Information provided by (Responsible Party):
Saint Francis Care
ClinicalTrials.gov Identifier:
NCT01454518
First received: October 6, 2011
Last updated: March 8, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to examine if ultrasound guided infiltration of local anesthetic solution around the hip joint will provide effective pain control after hip arthroscopy.
| Condition | Intervention |
|---|---|
|
Pain |
Procedure: Infiltration of local anesthetic Procedure: Normal Saline Injection |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver) Primary Purpose: Treatment |
| Official Title: | Effectiveness of Ultrasound Guided Hip Infiltration With Local Anesthetic Solution for Pain Control After Hip Arthroscopy |
Further study details as provided by Saint Francis Care:
Primary Outcome Measures:
- Post operative opioid consumption. [ Time Frame: Within 24 hours after surgery ] [ Designated as safety issue: No ]Amount in milligrams of opioid consumption post surgery in the recovery room and for a 24 hour period.
Secondary Outcome Measures:
- Pain scores in recovery room. [ Time Frame: Within 24 hours of the surgery ] [ Designated as safety issue: No ]Mesures of pain score using numeric pain rating scale (0=no pain, 10=worst pain) completed by patient in recovery room and every 6 hours for a 24 hour period after discharge from recovery room.
| Enrollment: | 36 |
| Study Start Date: | October 2011 |
| Study Completion Date: | February 2013 |
| Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Infiltration of local anesthetic
30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
|
Procedure: Infiltration of local anesthetic
30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
|
|
Placebo Comparator: Normal Saline Injection
injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
|
Procedure: Normal Saline Injection
injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
|
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- hip arthroscopy
- ages 18-80
Exclusion Criteria:
- history of neurological disease
- diabetes
- pregnancy
- neuropathy
- chronic narcotic use
- allergy to local anesthetic solution
- inability to give consent or cooperate with the study protocol
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01454518
Locations
| United States, Connecticut | |
| Saint Francis Hospital and Medical Center | |
| Hartford, Connecticut, United States, 06105 | |
Sponsors and Collaborators
Saint Francis Care
Investigators
| Principal Investigator: | Sanjay Sinha, M.D. | Saint Francis Memorial Hospital |
More Information
No publications provided
| Responsible Party: | Saint Francis Care |
| ClinicalTrials.gov Identifier: | NCT01454518 History of Changes |
| Other Study ID Numbers: | 11-08-003 |
| Study First Received: | October 6, 2011 |
| Last Updated: | March 8, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Saint Francis Care:
|
hip arthroscopy post operative analgesia |
Additional relevant MeSH terms:
|
Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions |
Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013